Nucleus RadioPharma
Nucleus RadioPharma: Innovating radiopharmaceutical manufacturing for enhanced cancer treatment.
Founded
2022Nucleus RadioPharma: Innovating radiopharmaceutical manufacturing for enhanced cancer treatment.
Nucleus RadioPharma was founded to ensure cancer patients have access to potentially life-saving radiopharmaceuticals. The company's core mission is to modernize the clinical development, manufacturing, and supply chain of these therapies. They offer services in product development and regulatory expertise, manufacturing infrastructure, and supply chain networks tailored to the unique demands of radioactive isotope-based products. Their market focus is on advancing promising drug candidates into commercially successful radiotherapeutics.
Notable affiliated people and investors include experts in radiopharmaceuticals and oncology, although specific names are not provided. Key achievements include the establishment of a reliable and efficient manufacturing footprint and an interconnected resource network. Nucleus RadioPharma's overall impact lies in its innovative approach to radiopharmaceutical manufacturing, significantly enhancing the availability and effectiveness of cancer treatments.
Companies similar to Nucleus RadioPharma include Radionetics Oncology, Illumina Radiopharmaceuticals, Radiomedix and NuView Life Sciences.
Nucleus RadioPharma was founded in 2022.
Nucleus RadioPharma's headquarters is located in Rochester, MN, US.
Nucleus RadioPharma's most recent funding round was for $56M (USD) in October 2023.
As of Oct 17, 2023, Nucleus RadioPharma has disclosed funding of $62M (USD). Undisclosed round amounts are excluded.
Nucleus RadioPharma has 30 employees as of Feb 4, 2024.
NuView Life Sciences
